现在还有多少有希望的新药？

中国先生ws

同上，感觉现在好压抑啊，没有一点正能量

newchinabok

Is a Cure for Hepatitis B Coming? Experts Say Yes
May 18, 2016 hepbtalk
How far are we from finding a cure for hepatitis B? We are close, said Timothy Block, PhD, president and co-founder of the Hepatitis B Foundation and its research arm, the Baruch S. Blumberg Institute. He points out that hepatitis C, once thought to be incurable, is today cured with new combination treatments.

Image courtesy of suphakit73 at FreeDigitalPhotos.net.
Image courtesy of suphakit73 at FreeDigitalPhotos.net.
Experts believe a cure for hepatitis B will also soon be developed. And the need for a cure has never been greater, with more than 240 million people worldwide living with chronic hepatitis B, causing 1 million deaths per year from related liver failure and liver cancer.

“Treatments are available,” explained Block, “but we have become a little too comfortable with the medications that are currently approved for use.” While these drugs are effective, interferon has many side effects and daily antivirals require lifelong use. These drugs work in only half of the infected population and reduce death rates by only about 40 to 70 percent.

What will a cure look like?

The available antivirals are similar and combining them offers no advantage. They have limited effectiveness against cccDNA, the seemingly indestructible “mini-chromosome” of the hepatitis B virus that continues to produce virus particles in infected liver cells, even in people being treated. A cure, therefore, would have to destroy or silence cccDNA and provide long-term immunity. Because one-drug treatments can lead to drug resistance, a cure would almost certainly involve combination therapy, similar to hepatitis C.

With the recent advances in hepatitis B research, scientists are optimistic that another big leap in the search for a cure is possible if new complementary drugs are identified. The Baruch S. Blumberg Institute of the Hepatitis B Foundation is at the forefront of research efforts to discover such new drugs.

Blumberg scientists have played a key role in increasing understanding of the virus life cycle and are designing and developing ways to test new drugs.

Hepatitis B Foundation President Timothy Block
Hepatitis B Foundation President Timothy Block
“With our Drexel University colleagues, we are among the first, if not the only group, to identify a small molecule that inhibits hepatitis B virus cccDNA formation,” Block noted. This is significant because inhibition of cccDNA is considered essential in achieving a complete cure. Block is confident that a drug that can accomplish this will be developed.

In 2015, the Blumberg Institute licensed several of its discoveries to Arbutus Biopharma, the first company solely dedicated to hepatitis B drug discovery, and signed a three-year research agreement to work on novel approaches to developing a cure. “This unique partnership will allow us to move our discoveries more rapidly from the lab to the clinic,” Block explained.

Adding to its drug arsenal, Blumberg researchers have used computer modeling to design and produce targeted drugs against hepatitis B and liver cancer. In another innovative approach, researchers are screening plant and fungal extracts from its Natural Products Collection, donated by Merck & Co. in 2011, and have already discovered two potential drugs that are active against hepatitis B.

Getting close to the finish line

“There has never been more optimism than right now that a cure is within reach,” said Block. “This is the goal of the Hepatitis B Foundation, so we are all very excited.” Blumberg researchers are building on recent discoveries that have heightened the momentum around finding a cure for hepatitis B and liver cancer: new screening methods to search for effective drugs; new ways to treat hepatitis B using different approaches to shut down the virus; a new blood biomarker that aids in the early detection of liver cancer; and a promising drug that selectively kills liver cancer cells in animal studies.

“The years that we all have spent working towards a cure for hepatitis B have laid the groundwork for this final phase,” said Block. “We are committing everything we have, every resource at our disposal, to developing the therapies that will ultimately improve the lives of all people living with hepatitis B worldwide and ultimately relegate hepatitis B to the history books.”

Drugs currently in development at the Blumberg Institute

cccDNA Inhibitors: Blumberg is the only group to identify the first small molecule inhibitor of HBV cccDNA, which has now been made highly active and is licensed to Arbutus Biopharma for further development.

Capsid Inhibitors, “YES Kinase” Inhibitors: It is using high-throughput screens and computer modeling to design and produce targeted drugs that include capsid inhibitors for hepatitis B and “YES kinase” inhibitors for liver cancer.

Immune System Activators: It has developed a new HBV drug that works by activating an infected liver cell’s own immune system, which has been shown to be effective in animal studies.

Natural Antiviral Agents: It has screened thousands of plant and fungal extracts from our extensive Natural Products Collection and identified two new leads that show potential activity against HBV.

   


antiviralBlumberg InstitutecccDNAHep B Awarenesshepatitis Bhepatitis B cureHepatitis B FoundationHepatitis B newshepatitis B researchPublic HealthResearch

newchinabok

http://www.hepb.org/blog/is-a-cu ... ng-experts-say-yes/

newchinabok

乙肝的治疗方法来了吗？专家说，是的
2016年5月18日hepbtalk
我们从乙型肝炎的治疗中有多远？我们是亲密的，Timothy Block说，博士，总裁和乙型肝炎基金会和研究机构的联合创始人，巴鲁克布隆伯格学院。他指出，丙型肝炎，曾经被认为是无法治愈的，今天是治愈与新的组合治疗。
在freedigitalphotos.net suphakit73礼貌的形象。
在freedigitalphotos.net suphakit73礼貌的形象。
专家认为，乙型肝炎的治疗也将很快得到发展。和需要一种治疗从来没有更大，超过2亿4000万人在世界各地的生活与慢性乙型肝炎，导致每年100万人死于相关的肝功能衰竭和肝癌。
“治疗是有效的，解释说：”块，“但我们变得有点过于舒适与目前批准使用的药物，而这些药物是有效的，干扰素和抗病毒药物有许多副作用日常需要终身使用。这些药物的工作只有一半的受感染的人口，并降低死亡率只有约40至百分之70。
一种治愈的方法是什么？
现有的抗病毒药物是相似的，并没有提供优势。他们有一定的抗cccDNA，看似坚不可摧的“微型染色体”的乙型肝炎病毒继续在感染的肝细胞产生病毒颗粒，甚至在人被处理。治愈，因此，需要销毁或沉默cccDNA和提供长期的免疫力。由于一种药物治疗能导致抗药性，几乎可以肯定的是一种治疗方法，包括联合疗法，类似于丙型肝炎。
随着乙型肝炎研究的最新进展，科学家们乐观地认为，如果新的补充药物被确定，另一个治疗方法的一个大的飞跃是可能的。巴鲁克S. Blumberg的乙型肝炎基础研究所是研究发现这种新药前列。
让科学家们发挥了关键作用，增加病毒生命周期的了解和开发测试新的药物设计方法。
乙型肝炎基金会主席Timothy Block
乙型肝炎基金会主席Timothy Block
“我们与卓克索大学的同事们，我们都是第一的，如果不是唯一的组，以确定一个小分子，抑制乙肝病毒cccDNA的形成，指出“块。这很重要，因为抑制cccDNA是实现一个完整的治疗被认为是必要的。块有信心，一种药物，可以完成这将是开发。
2015，布隆伯格所授权其几个发现杨梅生物制药，第一家专门致力于乙型肝炎药物的发现，并签署工作开发治疗新方法一项为期三年的研究协议。“这种独特的合作关系将使我们能够更迅速地将我们的发现从实验室转移到诊所，”块解释说。
增加药物的阿森纳，Blumberg的研究人员用计算机模型来设计和生产的靶向药物对乙型肝炎和肝癌。在另一种创新的方法中，研究人员正在筛选植物和真菌提取物，其天然产物的收集，由2011公司捐赠的，并已经发现了两种潜在的药物，对B型肝炎是积极的。
接近终点线
“从来没有比现在更乐观，治愈是在达到，说：”块。“这是乙型肝炎基金会的目标，所以我们都很兴奋，”布伦伯格的研究人员在最近的发现有加剧的势头周围寻找乙肝和肝癌治疗：新的筛选方法，寻找有效的药物；新的方法来治疗乙型肝炎使用不同的方法来关闭病毒；新的血液生物标志物，在肝癌的早期检测艾滋病；和一个很有前途的药物，选择性杀伤肝癌细胞在动物研究。
“我们都花了几年的工作，为乙型肝炎的治疗奠定了这最后阶段的基础，”说，块。“我们把我们所拥有的一切，我们所掌握的一切资源，发展治疗，最终将提高所有人乙型肝炎全球最终将乙型肝炎的历史书籍，生活的生活。”
在研究所目前正在开发的药物
cccDNA的抑制剂：Blumberg是识别HBV cccDNA的第一小分子抑制剂组，它现在已被高活性和被许可的杨梅生物制药的进一步发展。
“是激酶”抑制剂：它是使用高通量筛选和计算机建模设计和生产有针对性的药物，包括B型肝炎和“是激酶”抑制剂的肝癌的靶向药物。
免疫系统激活剂：它开发了一种新的乙型肝炎病毒药物

东霸天

ARC-520                ARC-521        只有这两种药有希望      其他的都不靠谱

newchinabok

靠谱，不靠谱都是心里安慰，就像拔牙打麻药一样，过了还是痛。正能量在我身上只管个一，二天。过了，还不是一个负能量，您说是不？正能量像手机样，一天一充，哈哈。

中国先生ws

我发病的时候，和家人说，我最多吃10年药就好了。已经两年了，8年够吗！

rxsm

央视记者：你幸福？
       泪人∶幸福！——王院士说乙肝已有特效药。

MP4

rxsm 发表于 2016-9-27 23:07
央视记者：你幸福？
       泪人∶幸福！——王院士说乙肝已有特效药。

他说的是丙肝